Embase: Under the hood in 10 mins at MLA 2012

•Download as PPTX, PDF•

1 like•831 views

It is a daunting task to try and explain the value of Embase and all its features in only 10 minutes, but our Product Manager, Daan De Jong, rose to the challenge and in case you missed any of his sessions, we’d like to share them with you. This one dives in to look at content and indexing.

Health & Medicine News & Politics

BLITS:
Getting the Best
from Embase: ‘UNDER THE HOOD’
EMBASE.com Key insights in (less) than 10 minutes...

Before we start...our history, heritage and future

Embase has been around for a while, but still evolving...

2

Step 1: Gathering resources...from different locations

More international focus?
YES, but not at the cost of our N-American coverage...!

3

...and from different disciplines and topic areas

Where’s the difference with Medline?
It’s in Pharmacology & Toxicology (+400
journals) &
General Clinical Medicine (+300
journals)

Other topics 28%

4

Step 2: Adding a taxonomy (Emtree) to the mix...

5

Step 3: Processing and indexing our records...

Articles Journal issue
(pre-pub) (published)

(160K records) (300K records)
<1 week <2 weeks

update update
Articles in In process Fully indexed
Press (AiPs) records (IPs) <1 week records
1m records
260K records 420K records

Deduplication
MEDLINE + conversion
(>700K records)
articles <1 week

single step 250K records
Journal (supp.) Conference
(published) abstracts

6

Step 4: Tracking our quality and currency...

We track Embase performance
in terms of quality and speed...
7

Step 5: Shipping Embase...

Access Embase through any vendor, Embase.com,
or our API... topics 28%
Other

8

Want to learn more...?

1. Subscribe to our Monthly newsletter at
http://www.embase.com/info/newsletter!

2. Go to embase.com/info

3. Or contact us now at
http://www.embase.com/info/contact-us!

9

In a world where startups grow to millions of users overnight and the Enterprise demands a tried and tested database we’ll start by examining MySQL’s relevance in a competitive marketplace where NoSQL and other relational databases claim to have it covered. It can often be difficult to identify exactly where the bottleneck lies and what the next move should be; we’ll discuss best practices for identifying the bottlenecks and the appropriate remedies from scaling vertically and horizontally to clustering and sharding. We’ll also discuss some of the issues that come with MySQL at scale and how we can maintain it with minimal downtime whilst still performing complex tasks.

NISO Webinar: What to Expect When You're Expecting a Platform Change: Perspec...

National Information Standards Organization (NISO)

In recent months, information providers have released a range of modifications to many abstracting and full text journal platforms. Whether an update to its look and feel or a radical restructuring of its search, browse, and full text features, any successful change to a familiar interface requires communication, tolerance, and understanding among the affected information provider, publisher(s), and library customers. Join NISO for a webinar in which a publisher and a librarian share their own experiences with determining priorities, learning lessons, and improving practices related to changed and changing information platforms.

Agile Innovation - Product Management in Turbulent times

Vasco Duarte

In today’s world we are constantly confronted with the message that the competition is breeding down our necks, that the market and environment are changing and we need to change with them. And most importantly, we are told that we need to listen to our customers to be able to provide the right products. We as a Product Managers need to be able to see beyond the basic product decisions, e.g. do we add feature A or feature B? We need to think beyond the silo of our function.

Absoft SAP OIl & Gas Supply Chain Forum - Optimising Inventory Management...

Absoft Limited

Architectures That Scale Deep - Regaining Control in Deep Systems

C4Media

Video and slides synchronized, mp3 and slide download available at URL https://bit.ly/2FWc5Sk. Ben Sigelman talks about "Deep Systems", their common properties and re-introduces the fundamentals of control theory from the 1960s, including the original conceptualizations of Observability & Controllability. He uses examples from Google & other companies to illustrate how deep systems have damaged people's ability to observe software, and what needs to be done in order to regain control. Filmed at qconsf.com. Ben Sigelman is a co-founder and the CEO at LightStep, a co-creator of Dapper (Google’s distributed tracing system), and co-creator of the OpenTracing and OpenTelemetry projects (both part of the CNCF). His work and interests gravitate towards observability, especially where microservices, high transaction volumes, and large engineering organizations are involved.

All scientific disciplines, including medicinal chemistry, are experiencing a revolution in unprecedented rates of data being generated and the subsequent analysis and exploitation of this data is increasingly fundamental to innovation. Using data to design better compounds is a challenge for Medicinal and Computational chemists. The design of small-molecule drug candidates, encompassing characteristics such as potency, selectivity and ADMET (absorption, distribution, metabolism, excretion and toxicity) is a key factor in the success of clinical trials and computer-aided drug discovery/design methods have played a major role in the development of therapeutically important small molecules for over three decades. These methods are broadly classified as either structure-based or ligand-based. In this webinar our expert Dr. Olivier Barberan will discuss ligand-based methods and he will cover the following: How to use only ligand information to predict activity depending on its similarity/dissimilarity to previously known active ligands. - Discuss ligand-based pharmacophores, molecular descriptors, and quantitative structure-activity relationships and important tools such as target/ligand databases necessary for successful implementation of various computer-aided drug discovery/design methods in a drug discovery campaign.

Webinar: New RMC - Your lead_optimization Solution June082017

Ann-Marie Roche

The document discusses Reaxys Medicinal Chemistry and how it supports hit-to-lead and lead optimization processes. It provides high quality data on topics like efficacy, ADMET properties, and animal models to help computational and medicinal chemists. The pX concept normalizes bioactivity measurements like IC50, Ki, and % inhibition into a single comparable metric, making it possible to compare compound affinity regardless of the metric reported. This allows researchers to more easily search for and analyze active compounds.

Oil&Gas Thought Leader Webinar - New Plays for Old Ideas - Dr.Gabor Tari

Ann-Marie Roche

In our April 2017 webinar, three industry experts shared their research and demonstrated the importance of focusing on fundamental geologic and geophysical research approaches that integrate variety of data, information and concepts from disparate sources and related disciplines. This back-to-fundamentals research can both inspire and accelerate exploration teams’ thinking about petroleum systems and lead to a path to success. Dr Gabor Tari is currently the Group Chief Geologist at OMV. He has over 20 years’ experience working in upstream oil & gas and has worked for Amoco, BP, and Vanco, before joining OMV in 2007. Gabor has worked on exploration projects in basins around the globe, including Romania, Angola, North Africa, and the Middle East. He has authored over 50 scientific publications, presented papers at dozens of conferences, and most recently co-authored the book Permo-Triassic Salt Provinces of Europe, North Africa and the Atlantic Margins, with Dr Joan Flinch (Repsol) and Juan Soto, Professor of Geodynamics in the Granada University and in the Instituto Andaluz de Ciencias de la Tierra, Spain, which is currently available from Elsevier for pre-order online. Gabor discussed and shared some examples of how new plays can be built on a solid foundation of petroleum system development and research, and how new ideas can be garnered from building on published research of oil & gas companies, academia, service providers and consultants.

Oil&Gas Thought-Leader Webinar - New Plays for Old Ideas - Dr. Rob Forkner

Ann-Marie Roche

Oil&Gas Thought-Leader Webinar - New Plays for Old Ideas - Dr. Sander Houben

Ann-Marie Roche

Dr. Sander Houben presented on combining paleoceanographic and exploration tools to study Early Jurassic anoxic events. He discussed how carbon isotopes can be used as a stratigraphic tool to analyze perturbations to the carbon cycle during these events. Palynological analysis of indicators of photic zone anoxia and chemocline migration provided insight into changes in water column ecology. A case study of the Toarcian OAE and Posidonia Shale Formation showed how isotopic analyses revealed a major increase in export of hydrogen-rich organic matter due to intensified primary productivity by diazotrophs under low oxygen conditions. Paleoceanographic observations combined with an exploration geology perspective provided understanding of the formation of

Embase for pharmacovigilance: Search and validation March 22 2017

Ann-Marie Roche

Scientific literature plays a critical role in Pharmacovigilance and Drug Safety workflows. Monitoring literature for mentions of adverse drug reactions (ADRs) is mandated by regulatory bodies, and marketing authorization holders (MAHs) that do not properly report ADRs can be subject to heavy fines. With an increasing volume of unstructured content to cover, along with rising labor costs, MAHs are looking for ways to make their literature monitoring more effective and efficient. Abstract and indexing (A&I) databases play an important role in Literature Monitoring – due to the vast amount of scientific literature published daily – in order for MAH’s to locate specific articles or conference presentations that may be relevant for their products (for both benefit/risk analysis and ADR detection). Rather than reading all the literature, MAH’s create search strategies that identify the relevant records in A&I databases and execute the searches regularly. GVP module VI mandates that searches are done at least weekly, but many companies maintain a daily monitoring and review cycle. In this webinar, Senior Product Development Manager Embase, Dr. Ivan Krstic discussed best practices for saving time, staying current, validating search strategies and mitigating risk in the face of these increasingly complex processes in literature monitoring

Literature Management for Pharmacovigilance: Outsource or in-house solution? ...

Ann-Marie Roche

Pharmaceutical companies are required to screen scientific literature on a regular basis and this comes with many challenges, such as handling large amounts of data, building search strings and integrating EMA MLM results. Out-sourcing literature screening to service providers reduces the workload for the PV-team, but how does it impact the literature management process overall? Maybe it results in decreased oversight and additional activities like audits and reconciliation? And what about building the search strategy? During this webinar our PV expert, Dr. Joyce De Langen spoke about the following: • The importance of literature management in Pharmacovigilance and the challenges. • An evaluation of the benefits and risks of outsourcing literature management versus alternative solutions. About the speaker: Joyce de Langen, Ph.D has more than 10 years of experience in the domain of pharmacovigilance and drug safety. Through her work in the pharmaceutical industry, academia and regulatory authorities, Joyce has developed a broad perspective and knowledge in pharmacovigilance and drug safety.

Finding the right medical device information in embase 11 2016

Ann-Marie Roche

The document discusses guidelines for systematic reviews of biomedical literature in Clinical Evaluation Reports (CERs) for medical devices, highlighting how Embase addresses the requirements through its comprehensive indexing of devices, manufacturers, and adverse effects, as well as features for building sensitive searches. It also provides examples of searches in Embase to find information on device clinical performance, comparisons, and safety for a case study on an everolimus eluting coronary stent.

Medical device reporting 27 sep2016

Ann-Marie Roche

The document discusses medical device adverse event reporting requirements, including definitions of reportable events and timelines for submitting reports to regulatory agencies. It provides an overview of the classification system for medical devices and regulations around reporting malfunctions, deaths and serious injuries caused by devices. Reporting requirements and challenges involving software as a medical device are also reviewed.

Eac webinar 09.21.2016

Ann-Marie Roche

Literature monitoring for pv what are we doing at galderma elsevier webinar

Ann-Marie Roche

The document discusses literature monitoring for pharmacovigilance. It describes weekly monitoring of individual case safety reports and periodic monitoring through development safety update reports and periodic benefit-risk evaluation reports. Key databases for literature searches are Medline and Embase. While Embase has more extensive drug coverage, searches on Medline via PubMed are more reliable due to the potential for loss of MeSH subheadings when mapping to Emtree and the risk of false negatives and positives when searching Embase alone. Literature searches support signal detection and periodic evaluation of a product's safety profile.

Drug analytics based on triple linking v1.0

Ann-Marie Roche

This document discusses how drug analytics based on manually extracted semantic relationships in Embase can be useful for drug development, repurposing, and safety. It describes how relationships between drugs, diseases, and adverse reactions that are manually indexed can provide valuable information for drug repurposing, development, and safety. Specific examples are provided to show how the semantic relationships can guide drug repositioning strategies, investigate new combination drugs, identify drug-drug interactions, collect drug comparison data, and help improve risk management.

Knovel lss webinar

Ann-Marie Roche

This document discusses Lean Six Sigma and resources available through Knovel to support Lean Six Sigma implementation. It provides an overview of the Lean Six Sigma implementation process including strategic leadership and vision, deployment planning, and execution and results. It describes Knovel's Lean Six Sigma resources such as handbooks, case studies, templates, and guides covering tools like DMAIC, DOE, SPC etc. that can help with the different belts and project phases from Define to Control. Other resources discussed include those for Design for Six Sigma and practical applications/case studies.

Reaxys rmc unified platform_ webinar_

Ann-Marie Roche

Reaxys provides a unified information portal that integrates data from multiple chemistry sources through a single interface. It links chemistry data, structures, citations, and full-text articles. Reaxys also integrates in-house data from sources like electronic lab notebooks through its API and can be used for activities like compound screening, literature searching, and patent analysis to support drug discovery.

Pathway studiosymposium lorenzi

Ann-Marie Roche

Phil Lorenzi discusses pathway analysis approaches and their uses in biomedical research and drug development. He compares strategies for analyzing the autophagy and apoptosis pathways, finding that integrating multiple methods provides the most comprehensive understanding. Lorenzi also provides examples of how pathway analysis could have predicted problems with COX-2 inhibitors and helped explain past failures of AKT inhibitors. He concludes that pathway analysis is consistent with approvals of EGFR, MEK, RANKL and PARP inhibitors and may support development of GLS inhibitors.

Searching literature databases for post authorisation safety studies (pass)

Ann-Marie Roche

This document discusses using literature databases like Embase to conduct post-authorization safety studies (PASS) through systematic literature reviews and meta-analyses. It provides an example PASS on the drug brentuximab vedotin that identified adverse events like peripheral neuropathy and infections. The document reviews how to structure a literature search using the PICO framework and Embase's in-depth indexing of concepts, relationships, and causality to comprehensively identify safety outcomes reported for a drug.

Julie glanville embase sunrise seminar may 2016

Ann-Marie Roche

Simple text mining tools can help Embase users in several ways: - Frequency analysis of terms in records can identify useful search terms and concepts to explore. Tools like EndNote and Voyant allow viewing frequencies of words in titles, abstracts, and subject headings. - Phrase analysis identifies common word combinations or concepts in the text, beyond single words. Voyant and TERMINE are useful for this. - Word collocation analysis shows which words frequently occur near each other, suggesting relationships between ideas. The Voyant collocates tool supports this. - Cluster and network visualizations identify major themes or concepts within a set of records. VOSviewer creates visual maps of related terms. Exploring records

Ian crowlesmith embase retrospective mla 2016

Ann-Marie Roche

Embase began in 1946 as Excerpta Medica, founded to provide medical abstracts. It was acquired by Elsevier in 1971 and became available online in 1978. Key developments included introducing a controlled vocabulary called Emtree in 1987 and adding item types and check tags for evidence-based medicine in 1990. Currently, Embase indexes articles in great depth using natural language and extensively covers drugs and devices. The taxonomy Emtree is regularly updated to reflect new terms.

Ivan krstic embase update mla 2016

Ann-Marie Roche

The document provides an update on new features and enhancements to Embase.com. Key points include: - The addition of a new PICO search page that allows users to build clinical searches by splitting questions into Patient, Intervention, Comparison, and Outcome elements. - Other enhancements include improved search tips, the ability to add synonyms and view all abstracts, as well as analytics capabilities for drug safety and repurposing based on triple indexing of content. - Future plans include improvements to content, taxonomy, and indexing as well as a revamp of the search platform interface and functionality.

Kp bloch psm preparedness final rev

Ann-Marie Roche

This document discusses upcoming changes to process safety management (PSM) regulations and standards. It notes several major industrial accidents in recent decades that prompted reforms. New PSM requirements in California will likely be adopted more widely and require more prescriptive tasks, reporting, and accountability. To ensure future PSM success, the document recommends: making no distinction between internal/external compliance; expanding the definition of mechanical integrity; understanding "double jeopardy"; not replacing investigations with management of change; knowing what the operations team is doing; and clarifying teamwork expectations regarding stop work authorizations.

Chapter 11 Nutrition and Chronic Diseases.pptx

Earlene McNair

Histopathology of Rheumatoid Arthritis: Visual treat

DIVYANSHU740006

Recently uploaded

Chapter 11 Nutrition and Chronic Diseases.pptx

Earlene McNair

Histopathology of Rheumatoid Arthritis: Visual treat

DIVYANSHU740006

All info about Diabetes and how to control it.

Gokuldas Hospital

Cell Therapy Expansion and Challenges in Autoimmune Disease

Health Advances

There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities. In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions. Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved. Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.

Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

Medical Quiz ( Online Quiz for API Meet 2024 ).pdf

Jim Jacob Roy

Artificial Intelligence Symposium (THAIS)

Josep Vidal-Alaball

Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes

PsychoTech Services

Physical demands in sports - WCSPT Oslo 2024

Torstein Dalen-Lorentsen

Histololgy of Female Reproductive System.pptx

AyeshaZaid1

Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.

Cardiac Assessment for B.sc Nursing Student.pdf

shivalingatalekar1

Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...

Oleg Kshivets

Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).

Integrating Ayurveda into Parkinson’s Management: A Holistic Approach

Ayurveda ForAll

Aortic Association CBL Pilot April 19 – 20 Bern

suvadeepdas911

CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf

rishi2789

Netter's Atlas of Human Anatomy 7.ed.pdf

BrissaOrtiz3

Abortion PG Seminar Power point presentation

AksshayaRajanbabu

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf

rishi2789

CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf

rishi2789

Role of Mukta Pishti in the Management of Hyperthyroidism

Dr. Jyothirmai Paindla

Recently uploaded (20)

Chapter 11 Nutrition and Chronic Diseases.pptx

Histopathology of Rheumatoid Arthritis: Visual treat

All info about Diabetes and how to control it.

Cell Therapy Expansion and Challenges in Autoimmune Disease

Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx

Medical Quiz ( Online Quiz for API Meet 2024 ).pdf

Artificial Intelligence Symposium (THAIS)

Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes

Physical demands in sports - WCSPT Oslo 2024

Histololgy of Female Reproductive System.pptx

Cardiac Assessment for B.sc Nursing Student.pdf

Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...

Integrating Ayurveda into Parkinson’s Management: A Holistic Approach

Aortic Association CBL Pilot April 19 – 20 Bern

CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf

Netter's Atlas of Human Anatomy 7.ed.pdf

Abortion PG Seminar Power point presentation

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf

CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf

Role of Mukta Pishti in the Management of Hyperthyroidism

Embase: Under the hood in 10 mins at MLA 2012

1. BLITS: Getting the Best from Embase: ‘UNDER THE HOOD’ EMBASE.com Key insights in (less) than 10 minutes...

2. Before we start...our history, heritage and future Embase has been around for a while, but still evolving... 2

3. Step 1: Gathering resources...from different locations More international focus? YES, but not at the cost of our N-American coverage...! 3

4. ...and from different disciplines and topic areas Where’s the difference with Medline? It’s in Pharmacology & Toxicology (+400 journals) & General Clinical Medicine (+300 journals) Other topics 28% 4

5. Step 2: Adding a taxonomy (Emtree) to the mix... 5

6. Step 3: Processing and indexing our records... Articles Journal issue (pre-pub) (published) (160K records) (300K records) <1 week <2 weeks update update Articles in In process Fully indexed Press (AiPs) records (IPs) <1 week records 1m records 260K records 420K records Deduplication MEDLINE + conversion (>700K records) articles <1 week single step 250K records Journal (supp.) Conference (published) abstracts 6

7. Step 4: Tracking our quality and currency... We track Embase performance in terms of quality and speed... 7

8. Step 5: Shipping Embase... Access Embase through any vendor, Embase.com, or our API... topics 28% Other 8

9. Want to learn more...? 1. Subscribe to our Monthly newsletter at http://www.embase.com/info/newsletter! 2. Go to embase.com/info 3. Or contact us now at http://www.embase.com/info/contact-us! 9

Editor's Notes

Embase has been around for a while; Technically Embase started roughly 60 years ago, as the ExcerptaMedica Abstract Journals in 1947. - With 50 abstract journals, that contained Emtree (taxonomy) indexing; The first major milestone was back in 1974, when the database of those abstract journals was made available digitally through, what was at the time: Lockheed Dialog. Over the years many platforms that provide access to Embase have come an gone, and currently it’s available on OvidSP, Proquest Dialog, STN, Ebsco, amongst others. Roughly 11 years ago Elsevier developed it’s own platform: embase.com, which has an interface specifically tailored for the embase dbase, indexing and taxonomy, with special attention to subheadings, deduplication at the source and conferences. New developments? Increased taxonomy and Embase API; existing customers can get access to that API for free. This presentation is meant for both Embase.com users as well as vendor customers!
Our more international coverage is true; yes we have more European, Asian and Latin American content, but not at a cost of our North American coverage; Roughly 2700 N-American journals in Embase; 2500 in Medline.
Our coverage is pretty similar to Medline, percentage wise, but clearly deviates on two topic areas; Pharmacology & Toxicology and General Clinical Medicine;
We track our currency for a selection of journals, just to make sure that we stay ahead of the game.

Embase: Under the hood in 10 mins at MLA 2012

Recommended

Recommended

More Related Content

More from Ann-Marie Roche

More from Ann-Marie Roche (20)

Recently uploaded

Recently uploaded (20)

Embase: Under the hood in 10 mins at MLA 2012

Editor's Notes